BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

aTyr Pharma (ATYR)aTyr PharmaEarnings

Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated. Company to prioritize strategic partnerships to advance Phase 3 study of efzofitimod in pulmonary

Related news

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

AVTXAvalo Therapeutics2026-11-05 12:00 EST

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

KNSAKiniksa2026-10-27 11:30 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

BMYBMYBristol-Myers Squibb Company2026-09-18 10:59 EST

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

SNGXSOLIGENIX2026-11-06 12:30 EST

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

MLTXMoonLake Immunotherapeutics2026-11-04 12:00 EST

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

View all latest news

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

ATYRaTyr Pharma2026-11-05 21:01 EST

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-10-29 12:00 EST

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

ATYRaTyr Pharma2026-10-27 13:00 EST

aTyr Pharma Announces One-for-40 Reverse Stock Split

ATYRaTyr Pharma2026-10-19 11:00 EST

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

ATYRaTyr Pharma2026-10-13 12:00 EST

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

Stock data

Close
6.03 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States